To read the full post, please click on the title.

Fueled by the pan-cancer genomics landscape and druggable targets discovered in The Cancer Genome Atlas (TCGA), and great successes of clinically actionable pharmacogenetic variants, precision medicine is one of the driving forces for biomedical research. It is becoming...[read more]
  • 15 March 2017
  • Author: Lang Li, PhD
  • Number of views: 59
  • Comments: 0
Immunotherapy has burst into oncology drug development during recent years by demonstrating some amazing responses in indications earlier associated with a poor prognosis. The immune checkpoint inhibitors act by restoring and stimulating the patient’s own...[read more]
On Nov 21, 2016, the European Medicines Agency (EMA) hosted a workshop to discuss its draft guideline on qualification and reporting of physiologically-based pharmacokinetic (PBPK) analysis.  The “first-of-its-kind” guideline, published earlier on July 21, 2016, proposes...[read more]
  • 6 January 2017
  • Author: Ping Zhao, PhD
  • Number of views: 993
  • Comments: 0
Do time-to-tumor-growth (TTG) metrics need to be corrected for time-dependent bias in pharmacometric oncology models?
A main objective of the application of pharmacometrics in oncology is to develop drug-independent models to link tumor-growth-inhibition (TGI) metrics, such as...[read more]
This month, PSP features a contribution from Pelligrand et al.1, the topic of which is unusual for PSP in the sense that the paper does not relate (directly or indirectly) to human pharmacology, but is concerned with a population pharmacokinetic analysis of robenacoxib in...[read more]
528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |